Factor XI deficiency is a rare disease found predominantly in Ashkenazi Jews. There is a poor correlation between factor XI level and bleeding in patients with factor XI deficiency. Individuals with severe factor XI deficiency are usually at risk of excessive bleeding after surgery and injury, particularly when trauma involves tissues rich in fibrinolytic activity. Women with partial or severe deficiency are at risk of excessive uterine bleeding during labor. The unpredictable nature of factor XI deficiency complicates management during pregnancy and delivery. This review gives an overview of the management of pregnant women with factor XI deficiency.
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Role of Factor XI in Coagulation
Factor XI (FXI) is the inactive precursor (zymogen) of a plasma serine protease that activates factor IX (FIX), and thus contributes to the consolidation phase of coagulation by augmenting thrombin generation on the surface of activated platelets. 1 Historically, FXI was thought to play a crucial role in the intrinsic coagulation cascade after activation by FXIIa. However, this concept changed when it was shown that the physiological activator of FXI is actually thrombin formed on the surface of platelets through the tissue factor-FVIIa pathway. It has been suggested that one of the FXI subunits binds to the platelet membrane, whereas the other binds to FIX resulting in efficient thrombin activation. The sustained generation of thrombin even after clotting activates thrombin activatable fibrinolysis inhibitor (TAFI), impeding the conversion of plasminogen to plasmin, and thus leading the stability of the forming blood clot. 2 Hence, FXI serves as procoagulant and antifibrinolytic agent, and the lack of it in plasma results in a bleeding tendency. The gene encoding FXI is located on the distal arm of chromosome 4 (4q35). Factor XI is synthesized in the liver and circulates in plasma as a complex with high-molecular-weight kininogen. It has a half-life of about 52 hours. 3 
Genetic Basis
Deficiency of FXI was originally described in 1953 in a Jewish family and has been historically called ''hemophilia C,'' ''plasma thromboplastin antecedent deficiency,'' and ' 'Rosenthal syndrome.'' 4, 5 This bleeding disorder, presently known as ''FXI deficiency,'' is a rare disease that occurs in general populations at a frequency of 1 per million. 6 However, the frequency of this condition is much higher in certain populations, notably among those of Ashkenazi. 7 It is one of the most common genetic disorders in this population with a heterozygous frequency of 9% and a homozygous frequency of 0.22%. 6 Four mutations (types I-IV) have been described in Jewish communities, of which type II (a nonsense mutation in exon 5) and III mutations (a missense mutation in exon 9) account for 98% of the mutant alleles. 5 In fact, FXI deficiency is found in all Jewish populations, although Ashkenazi Jews have the highest incidence as a consequence of the presence of both common mutations. These mutations are detected by polymerase chain reaction and restriction enzymes making carrier detection and prenatal diagnosis possible in this population. 8 However, the situation is different in non-Jews because of the larger number of mutations causing FXI deficiency in this group. Reports on the inheritance patterns for FXI deficiency are conflicting. It was initially considered to be an autosomal dominant disorder with variable expressivity based on clinical symptoms and family histories. However, Rapaport et al made a distinction between major (homozygous or compound heterozygous) and minor (heterozygous) variants, and it was described as having an incompletely recessive or ''intermediate'' mode of inheritance, with few symptoms occurring in heterozygotes. 9 Subsequent studies supported this hypothesis and led to the general opinion that FXI deficiency in Jewish patients is a recessive disorder. Not all cases of FXI deficiency are consistent with a simple autosomal recessive model; there are families in whom transmission from a single affected parent to child appears to be consistent with a dominant form of transmission. The nature of the genetic abnormality responsible for the deficiency state contributes to the pattern of disease transmission. Mutations that interfere with transcription and prevent synthesis of the FXI polypeptide or that result in an abnormal protein that cannot dimerize might be expected to behave in an autosomal recessive manner. Mutations that result in synthesis of dysfunctional polypeptides that form dimers may produce a dominant type of disorder by generating dysfunctional heterodimers with wild-type FXI polypeptide. 10 
Clinical Manifestations
Individuals who are homozygous or compound heterozygous for the mutation have FXI levels of <15 to 20 U/dL and are called severely deficient. Individuals who are heterozygous are called partially deficient and have factor XI levels between 15 and 20 U/dL and the lower limit of the normal range, which is variably defined. 11 Many hospitals quote 50 U/dL, but caution is needed because individuals have been reported to have a bleeding tendency with factor XI levels between 50 and 70 U/dL. 12 Individuals with severe factor XI deficiency are usually at risk of excessive bleeding after surgery and injury, particularly when trauma involves tissues rich in fibrinolytic activity, such as the oral and nasal mucosa and genitourinary system. 13 However, paradoxically, some people with a severe deficiency do not have a bleeding tendency. 12 Unlike patients with severe hemophilia A or B, spontaneous bleeding is not usually a feature in FXI deficiency, but it can occur. Spontaneous hemarthroses are rare but have been reported even in individuals with partial deficiency. 14 It is well recognized that there is a poor correlation between FXI level and bleeding in patients with FXI deficiency. Some patients with a severe deficiency may not bleed at all following trauma, whereas some heterozygotes have excessive bleeding after a trauma. 15 The tendency to bleed may also vary in the same individual. Possibly, the bleeding risk is more dependent on the amount of FXI in platelets than the plasma level, but the evidence for this is limited. The patient's genotype, site of any surgery, and the presence of additional coagulation factor defects, most commonly von Willebrand disease, can all influence the patient's bleeding tendency. [16] [17] [18] [19] Treatment Replacement therapy consists of fresh frozen plasma or FXI concentrate. 20 Fresh frozen plasma was the main method of treatment until the advent of FXI concentrate. The disadvantages of the former include the large volume of fluid required, allergic reactions, and the variable half-life of fresh frozen plasma, ranging from 10 to 60 hours. 21 Two FXI concentrates are currently available: Hemoleven (Laboratoire français du Fractionnement et des Biotechnologies [LFB], Les Ulis, France) and factor XI concentrate (Bio Products Laboratory [BPL], Elstree, Hertfordshire, United Kingdom). Both products are FXI concentrates with double-viral inactivation and a mean half-life of 52 hours. Because of the thrombotic potential of these concentrates, antithrombin, heparin, and C 1 -esterase inhibitor are added. 22 These products are hemostatically effective and virus inactivated, but should be used with caution especially in elderly people with preexisting cardiovascular disease and in other individuals with preexisting coagulation activation (pregnant or puerperal women, patients with malignant disease). It also poses a small risk of inhibitor development, especially in severely deficient patients.
The use of recombinant factor VIIa (rFVIIa) in FXI deficiency was first reported in 1990 when rFVIIa was used to prevent surgical bleeding in a patient with an FXI inhibitor undergoing orchidectomy. Since then, a small number of case reports in patients with and without inhibitors have confirmed that rVIIa is effective in preventing surgical hemorrhage. 23, 24 It has the advantages of being a recombinant product with a much lower risk of thrombosis but is extremely expensive.
Desmopressin (DDAVP) has been used successfully to prevent surgical bleeding in FXI deficient patients. Although the mechanism by which DDAVP increases FXI levels is still not clear, some reports suggest that this drug is effective in preventing surgical bleeding in patients with mild FXI deficiency. 25, 26 
Pregnancy in Women with Factor XI Deficiency
Women with partial or severe deficiency are at risk of excessive uterine bleeding during labor. The unpredictable nature of FXI deficiency complicates management during pregnancy and delivery, and attempts should be made to identify whether the patient has a bleeding tendency and whether other factors are involved, such as the coexistence of von Willebrand disease or platelet function disorders. There are few data on pregnancy complications and FXI deficiency. [27] [28] [29] Factor XI usually remains constant throughout pregnancy, but some studies report an increase and others a fall in levels with advancing gestation. As it is often not feasible to check levels in an acute situation, routine monitoring should be performed at confirmation of pregnancy, 28th and 34th weeks of gestation, and prior to invasive procedures. Guidelines for women with bleeding disorders by United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) recommended that patients with FXI levels <15 U/dL should receive prophylactic treatment with FXI concentrate (or, if unavailable, fresh frozen plasma) at the onset of labor or prior to planned induction or cesarean section and after every 48 hours, at doses of 15 U/kg with the aim at maintaining FXI level of 30 U/dL or more during labor and for 3 to 4 days after vaginal delivery and 6 to 7 days after cesarean section. 30 In view of the thrombotic potential of the FXI concentrate, peak levels should not exceed 70 U/dL, and attention should be given to simple thromboprophylactic measures including maintenance of adequate hydration and early mobilization. In patients with levels between 15 and 50 to 70 U/dL, tranexamic acid should be given orally or intravenously, at doses of 1 g 6 to 8 hourly if there is a bleeding history or if this is unknown due to the absence of previous hemostatic challenges. Tranexamic acid is a fibrinolytic inhibitor that competitively inhibits the activation of plasminogen and noncompetitively inhibits plasmin, thus counteracting increased fibrinolysis in the uterus. The concomitant use of tranexamic acid and FXI concentrate should be avoided because this might increase the risk of thrombotic complications. Otherwise, some authors prefer to keep prophylactic treatment available for patients who develop excessive bleeding. Salomon et al 29 reported on incidence of postpartum hemorrhage in 62 women with severe FXI deficiency in 2005. In all, 70% of patients had uncomplicated deliveries despite receiving no FXI concentrate or fresh frozen plasma. Recently, Myers et al 31 reported on incidence of miscarriage, antenatal and postnatal hemorrhage in 105 pregnancies of 33 women with FXI deficiency who did not receive prophylactic treatment with FXI concentrate or fresh frozen plasma. Each woman was classified into bleeder or nonbleeder according to the criteria used by Bolton-Maggs et al. 27 Pregnancy and delivery was uneventful in 70% of the cases. Postpartum hemorrhage appears increased in women with a bleeding phenotype with a highly significant difference between bleeders and nonbleeders. Miscarriage rate appeared unchanged. It must be underlined that only 3 patients in this study have FXI levels <15 U/dL. These studies suggest that the use of prophylactic treatment at the onset of labor or prior to planned induction or cesarean section is not mandatory in women with severe FXI deficiency and can be reserved for patients who develop excessive hemorrhage. The problem with the studies of Salomon and Myers were retrospective and not randomized. The use of regional anesthesia in patients with bleeding disorders has always been controversial because of the risk of spinal hematoma causing acute spinal cord compression and irreversible paraplegia. Epidural anesthesia has been carried out without complication in FXI deficient patients; however, the consequences of a spinal hematoma with compression of the spinal cord makes it an unacceptable risk, and epidural techniques should be avoided in severe cases or in women with a significant bleeding history. If an epidural approach is necessary, it should be covered with FXI concentrate. Fresh frozen plasma contains variable levels of FXI, and it is not recommended to cover epidural anesthesia. Neonatal hemorrhage due to peripartum events is rare; however, care should be taken to avoid unnecessary trauma to the baby, and therefore it should be delivered by the least traumatic method. Prolonged labor and especially a prolonged second stage of labor should be avoided and early recourse to cesarean section should be considered. Although vacuum extraction should not be used, low forceps delivery can be considered less traumatic than a cesarean section when the head is deeply engaged in the pelvis and delivery can be achieved as an easy outlet procedure performed by an experienced obstetrician. Mid-cavity forceps and forceps involving the rotation of the head should be avoided. 27 Although fetuses affected by any bleeding disorder are potentially at risk of scalp hemorrhage from the use of fetal scalp electrodes and fetal blood sampling for intrapartum monitoring, there is a lack of published data to support this. No bleeding complications have so far been reported that affected fetuses and neonates with these procedures. Perhaps, they have not been used frequently in these situations. However, it is probably advisable to avoid their use in fetuses at risk. Spontaneous bleeding in the neonatal period has not been reported, but a cord blood sample should be taken at birth to determinate factor XI level and potential for bleeding during high-risk situations. Nevertheless, because neonatal levels are reduced to approximately 50% of adult levels (mean values of 38, 53, and 69 U/dL have been reported at days 1, 30, and 90 of age, respectively, in healthy full-term babies), a mild FXI deficiency cannot be reliably diagnosed and repeat testing during the first year of life may be indicated. Intramuscular injections should be avoided until the coagulation status is known, and vitamin K given orally if levels are reduced. 15, 32 Discussion Pregnancy in women with FXI deficiency requires specialized and individualized care provided collaboratively by an obstetrician, hematologist, and anesthetist. Given the unpredictability of the condition, attempts should be made to identify the individual's clinical bleeding tendency and the coexistence of any confounding factors. 32 Guidelines for women with bleeding disorders by UKHCDO recommended that patients with FXI levels <15 U/dL should receive prophylactic treatment with FXI concentrate or, if unavailable, fresh frozen plasma at the onset of labor or prior to planned induction or cesarean section. Otherwise, some authors prefer to keep prophylactic treatment available for patients who develop excessive bleeding. Nowadays, there is an open debate whether prophylactic treatment is necessary in all women with severe FXI deficiency. The only definitive way to answer the question requires future randomized studies. In the absence of this, the risks and benefits of treatment should be discussed with each woman at the time of the delivery. 33 
